Skip to content
Subscriber Only
Opinion
Mark Gongloff

From Fish Oil to Miracle Drug: Weekend Edition

Here are Bloomberg Opinion’s top stories this week.

Tastes bad, but good for you.

Tastes bad, but good for you.

Photographer: Science & Society Picture Library/SSPL

When medical breakthroughs are announced, they often affect a surprisingly small number of people. Many new drugs these days are targeting rare diseases or niche patient groups, and their impact is further restricted by price. 

Monday’s results from Amarin Corp.’s test of purified fish oil Vascepa in people at risk for heart diseases are an exception — and one more likely than any recent drug outcome to affect the average person reading this column.